Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jul 16, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell

This study investigated the effects of fixed-dose (FD) and weight-based (WB) dose plerixafor (Mozobil) on hematopoietic stem cell (HSC) movement in patients with Non-Hodgkin’s lymphoma (NHL) weighing less than 11 stone. The main finding was that there was no significant difference in HSC movement with WB or FD plerixafor.

Some background

HSCs are stem cells located in the bone marrow. Plerixafor and granulocyte-colony stimulating factor (G-CSF; Filgrastim) are therapies commonly used in NHL. Plerixafor and G-CSF are used in combination to cause HSCs to move from the bone marrow to the blood. These SCs are then collected and transplanted. SC transplantation is a common treatment for NHL. Plerixafor is currently administered as a fixed dose. This means that each patient gets the same quantity of the medicine. Weight based means the dose is calculated based on each individual patient’s body weight.  It is important to investigate the effects of different types of dosing of plerixafor on HSC movement in NHL patients.

Methods & findings

Sixty-one patients with NHL were included in this study. To cause HSC movement, all patients were administered G-CSF for 4 days. Thirty patients then received 20mg FD plerixafor. Thirty-one patients received 1.53mg/stone plerixafor (WB).

There was no significant difference in HSC movement between the two treatment groups. The patients who received FD had greater levels of plerixafor than those who received WB dose. However, this had no impact on HSC movement. Plerixafor appeared to have the same safety when administered as a FD or WB dose.

The bottom line

This study suggests that there is no significant difference in HSC movement in patients with NHL weighing less than 11 stone who received FD or WB plerixafor.

The fine print

This study included on a small number of patients. Therefore the results may not be representative of a larger population with NHL.

What’s next?

If you have questions about your NHL, please ask your doctor.

Published By :

Bone Marrow Transplantation

Date :

Jun 12, 2018

Original Title :

A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin’s lymphoma weighing ≤70 kg.

click here to get personalized updates